We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Trazodone (Desyrel) — serotonin antagonist and reuptake inhibitor (SARI) antidepressant, used off-label at low dose for insomnia
A prescription antidepressant that is FDA-approved only for major depressive disorder but is prescribed overwhelmingly OFF-LABEL at low dose (around 50 mg) as a sleep aid — in the US it is the second most commonly prescribed agent for insomnia. The evidence for that use is much thinner than the prescribing volume suggests: the American Academy of Sleep Medicine's clinical practice guideline suggests clinicians NOT use trazodone for sleep-onset or sleep-maintenance insomnia, a weak recommendation against. It is not a benign sleep aid — it causes next-day cognitive and motor impairment, orthostatic hypotension and falls, QT prolongation, serotonin syndrome when combined with other serotonergic drugs or supplements, and rarely priapism, a urological emergency.
Prescription medication — not a dietary supplement
Trazodone is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Trazodone studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2011–2024 with a typical study size of 30 participants.
Based on 13 studies · 3 meta-analyses · 2 RCTs · 8,982 total participants
Confidence
High confidenceBy outcome
2 more outcomes with fewer studies not shown.
Trazodone is one of the most-prescribed sleep medicines in the US, but the evidence for that off-label use is weak and the score reflects the evidence, not the popularity. The only meta-analysis dedicated to trazodone for insomnia (7 trials, 429 patients) found no significant benefit on sleep efficiency, sleep latency, total sleep time or wake-after-sleep-onset — only fewer awakenings and a borderline (P = 0.05) improvement in perceived sleep quality. The AASM clinical practice guideline suggests clinicians NOT use trazodone for sleep-onset or sleep-maintenance insomnia (a WEAK recommendation against). Positive trials exist but are very small (n = 16 and n = 30) and short, and the underlying literature is largely in depressed or demented populations. Against that sits a genuine harm profile: next-day cognitive and motor impairment, fall-related injury no lower than with benzodiazepines, orthostatic hypotension, QTc prolongation, serotonin syndrome in combination, and priapism.
Trazodone is a serotonin antagonist and reuptake inhibitor (SARI): it blocks 5-HT2A and 5-HT2C receptors while also inhibiting serotonin reuptake, and its sedating effect at low doses is attributed principally to antagonism of 5-HT2A, histamine H1, and alpha-1 adrenergic receptors. It is metabolised by CYP3A4 to m-chlorophenylpiperazine (mCPP), an active metabolite that is a more potent serotonin-reuptake inhibitor than the parent drug. Its only FDA-approved indication is major depressive disorder, where outpatient dosing runs up to 400 mg/day in divided doses (up to 600 mg/day in monitored inpatients). Almost nobody takes it that way. Off-label use for insomnia has surpassed its use as an antidepressant, and in the United States it is the second most commonly prescribed agent for insomnia — typically around 50 mg at bedtime, an order of magnitude below the antidepressant range.
The evidence does not match the prescribing volume. A 2018 meta-analysis of seven randomised placebo-controlled trials (429 patients) found NO significant improvement in sleep efficiency, and no significant difference from placebo in sleep latency, total sleep time, or wake time after sleep onset. What it did find was a reduction in the number of awakenings and a borderline improvement in self-reported sleep quality (SMD -0.41, 95% CI -0.82 to -0.00, P = 0.05). In other words: a subjective and sleep-maintenance signal, not an objective sleep-onset one. The American Academy of Sleep Medicine's GRADE-based clinical practice guideline concluded: "We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK)." A 2022 Lancet network meta-analysis of 170 insomnia trials likewise placed trazodone among licensed drugs that "can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available" — and trazodone was not among the agents shown to beat placebo on the primary efficacy outcome. Much of the underlying literature is small, short (days to a few weeks) and conducted in depressed or demented populations rather than in otherwise-healthy people with primary insomnia.
The two trials that do show something are instructive about the trade-off. In 16 primary insomniacs, trazodone 50 mg for 7 nights reduced night-time awakenings and Stage 1 sleep and increased slow-wave sleep by day 7 — while producing small but statistically significant next-morning impairments of short-term memory, verbal learning, equilibrium (body sway) and arm muscle endurance. In 30 community-dwelling Alzheimer's patients with sleep disturbance, trazodone 50 mg increased actigraphic sleep by 42.5 minutes per night over two weeks without daytime sedation or cognitive decline. Both are real effects; both are tiny studies.
The safety profile is the part most often glossed over. Trazodone is serotonergic, and serotonin syndrome has been reported when it is combined with SSRIs, SNRIs and other serotonergic agents — which extends to serotonergic supplements such as 5-HTP, St John's wort and SAM-e. It causes orthostatic hypotension and falls; in a matched cohort of 7,791 nursing-home residents, new low-dose trazodone was no safer than new benzodiazepine use for fall-related injury (5.7% vs 6.0% at 90 days, HR 0.94, 95% CI 0.83-1.08). It is associated with QTc prolongation. And it is the psychotropic most associated with priapism reports; a case series of drug-induced priapism attributes the mechanism to alpha-adrenergic blockade and notes it can occur at nearly any age and any dose. Priapism is a medical emergency. As an antidepressant it also ranks poorly: in the Lancet network meta-analysis of 21 antidepressants, trazodone was among the least efficacious drugs in head-to-head trials and among those with the highest dropout rates. Trazodone is a prescription drug, not a supplement, and it should not be treated as a low-stakes sleep aid.
Trazodone is a 5-HT2A and 5-HT2C receptor antagonist and a serotonin reuptake inhibitor — the 'SARI' profile. This dual action is also why it is serotonergic enough to contribute to serotonin syndrome when stacked with other serotonergic drugs or supplements.
The hypnotic action at the low doses used for sleep is attributed primarily to antagonism of 5-HT2A receptors, histamine H1 receptors, and alpha-1 adrenergic receptors. The same alpha-1 blockade drives orthostatic hypotension and is the presumed mechanism of trazodone-induced priapism.
Trazodone's most active metabolite, m-chlorophenylpiperazine (mCPP), is produced by CYP3A4 and is a more potent inhibitor of serotonin reuptake than trazodone itself. Anything that shifts CYP3A4 activity or co-prescribed drug levels shifts mCPP exposure — a case series of psychotropic-induced priapism specifically flagged plasma-concentration changes from dose changes or SSRI co-medication as a trigger.
In a poison-centre review of 1,125 supratherapeutic exposures — of which 760 had a documented QTc — trazodone was statistically associated with QTc > 500 ms in that subset — although life-threatening dysrhythmias were rare overall in that cohort.
How Trazodone works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
High caution. Low-dose trazodone was NO safer than benzodiazepines for fall-related injury in a matched cohort of 7,791 residents (5.7% vs 6.0% at 90 days). Combine with orthostatic hypotension and next-morning balance impairment and the fall risk is substantial. It is not the 'safe alternative to a benzo' it is often assumed to be.
Serotonin syndrome risk — this includes SSRIs, SNRIs, MAOIs, some antipsychotics, and serotonergic supplements such as 5-HTP, St John's wort, SAM-e and L-tryptophan. Give the prescriber a complete list of everything you take, supplements included.
Be told about priapism before the first dose — patients are frequently not warned about it, and delayed presentation is what causes lasting harm, with trazodone the leading drug involved. Any erection lasting beyond about four hours or unrelated to arousal is an emergency.
Discuss with the prescriber before starting; trazodone has been associated with QTc > 500 ms.
If depression is the actual problem, trazodone is a poor first choice on the comparative evidence — in the network meta-analysis of 21 antidepressants it was among the least efficacious in head-to-head trials and among those with the highest dropout rates.
Trazodone is not approved for anyone under 18, and the FDA boxed warning covers pediatric AND young adult patients: antidepressants raised the risk of suicidal thoughts and behaviours in short-term trials in these age groups. It should not be used off-label for sleep in this population without specialist supervision and active monitoring for mood change.
SEROTONIN SYNDROME. Trazodone inhibits serotonin reuptake and its CYP3A4-derived metabolite mCPP is an even more potent reuptake inhibitor; adding it to another serotonergic antidepressant can produce a potentially life-threatening excess of serotonin (neuromuscular excitation, autonomic instability, altered mental status). A published case describes serotonin syndrome after rapid titration of trazodone with sertraline. This combination is nonetheless prescribed deliberately in some settings — it must be a clinician's decision, with monitoring.
Serotonin syndrome risk. Serotonin syndrome can also present as a hypertensive crisis. Do not combine.
These raise serotonergic tone by the same final pathway as serotonergic drugs, so combining them with trazodone carries serotonin syndrome risk. This is a RISK, not a synergy — do not stack them to 'boost' sleep or mood. Tell the prescriber about every supplement you take.
Published cases describe serotonin syndrome precipitated when risperidone or quetiapine was added to trazodone plus sertraline. Serotonergic burden is cumulative across a regimen, not per-drug.
CYP3A4 produces trazodone's active metabolite mCPP, so drugs that alter CYP3A4 shift the exposure to both. A psychotropic priapism case series specifically identified changes in drug plasma concentration — from dose changes or from co-medication with certain SSRIs — as a trigger for priapism.
Additive sedation on top of trazodone's own measurable next-morning impairment of memory, balance and muscle endurance. In nursing-home residents, low-dose trazodone alone already matched benzodiazepines for fall-related injury risk.
Trazodone was statistically associated with QTc > 500 ms in a poison-centre review of supratherapeutic exposures. Stacking QT-prolonging agents compounds the risk; discuss with the prescriber, especially with known long QT, electrolyte disturbance, or cardiac disease.
Trazodone can cause orthostatic hypotension via alpha-1 blockade; added to blood-pressure-lowering therapy this increases the risk of dizziness on standing and falls.
Tip: The most common adverse reaction, and dose-dependent. Report persistent daytime sleepiness to the prescriber — one participant in the primary-insomnia trial withdrew for excessive sedation.
Tip: Dose-dependent; report to the prescriber if persistent.
Tip: Measured the morning after 50 mg in primary insomniacs. Do not drive or do anything requiring balance or fine motor control until you know how it affects you; the impairments were measured across time-points rather than shown separately for each day.
Tip: Stand up slowly. Particularly important in older adults, where low-dose trazodone carried the same fall-related injury risk as benzodiazepines over 90 days.
Tip: Trazodone was associated with QTc > 500 ms in supratherapeutic exposures, though life-threatening dysrhythmias were rare. Tell the prescriber about cardiac history, other QT-prolonging drugs, and any fainting or palpitations. Note the QTc signal comes from supratherapeutic/overdose exposures, so it does not establish a frequency at normal sleep doses.
Tip: Agitation, diaphoresis, tremor, myoclonus, hyperreflexia, fever, altered mental status — most often when trazodone is combined with other serotonergic agents. Seek emergency care immediately; it is treated by stopping the serotonergic drugs plus supportive care.
Tip: A prolonged erection unrelated to arousal is a UROLOGICAL EMERGENCY — go to an emergency department immediately; delay risks permanent damage. It can occur at nearly any age and with any dose, and prolonged erections are an early warning sign that must be reported at once.
Tip: Risk concentrated in older adults and those on diuretics. Confusion, headache, unsteadiness or new weakness warrant a sodium check rather than being written off as sedation.
Trazodone has an evidence score of 3.8/10 — emerging evidence based on 13 indexed studies, including 3 meta-analyses. A prescription antidepressant that is FDA-approved only for major depressive disorder but is prescribed overwhelmingly OFF-LABEL at low dose (around 50 mg) as a sleep aid — in the US it is the second most commonly prescribed agent for insomnia. The evidence for that use is much thinner than the prescribing volume suggests: the American Academy of Sleep Medicine's clinical practice guideline suggests clinicians NOT use trazodone for sleep-onset or sleep-maintenance insomnia, a weak recommendation against. It is not a benign sleep aid — it causes next-day cognitive and motor impairment, orthostatic hypotension and falls, QT prolongation, serotonin syndrome when combined with other serotonergic drugs or supplements, and rarely priapism, a urological emergency. Representative study: PMID 35843245.
The commonly studied dose of Trazodone is Prescription only — a clinician sets the dose. The doses studied for sleep are low: the placebo-controlled trials that show anything used 50 mg at bedtime (30 min before bed in the primary-insomnia study; 10 PM in the Alzheimer's study), and the systematic-review literature treats <100 mg/day as the 'low-dose' insomnia range versus ≥100 mg/day as the antidepressant range. This is entirely OFF-LABEL. The approved indication is major depressive disorder, where outpatient dosing goes up to 400 mg/day in divided doses (up to 600 mg/day in monitored inpatients).. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Trazodone is before bed. It can be taken on an empty stomach. Taken at bedtime for the hypnotic effect — 30 minutes before bed in the primary-insomnia trial, at 10 PM in the Alzheimer's trial.
Trazodone should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are drowsiness / daytime sedation, dizziness and dry mouth, next-day cognitive and motor impairment (memory, verbal learning, balance, muscle endurance). Use caution if any of these apply to you: Concurrent MAO inhibitors, or within the washout period after stopping one — risk of serotonin syndrome; Known hypersensitivity to trazodone; Anyone without a prescription — trazodone is a prescription antidepressant, not a supplement.
Melatonin
Likely helpsRegulates the circadian clock to reduce sleep onset time — most effective at low doses (0.3-1mg) for jet lag and rhythm disorders.
Tart Cherry
Likely helpsNatural melatonin and anthocyanin source with modest, fairly consistent small-RCT support for post-exercise recovery and sleep quality, plus uric-acid lowering — effects are real but small and not seen in every trial.
Magnesium
Likely helpsSupports 300+ enzymatic reactions — critical for sleep, stress response, muscle function, and cognitive health.
Ashwagandha
Likely helpsReduces cortisol and anxiety while improving sleep quality and physical recovery in stressed adults.
Explore: Best supplements for Sleep
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 13 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research